A statement from the Bionical Emas Group on guidance & measures regarding COVID-19 - read here

In relation to staff and visitor safety, we have full risk assessments in place for all of our workplaces. These risk assessments are revisited and updated regularly, to reflect changing risks, knowledge and circumstances, and to reflect evolving Government guidance. We have not placed the risk assessments here on the website as they would become out of date too quickly. However, you are welcome to email info@bionical-emas.com to request access to our most up to date risk assessments applicable to your needs. Please note that all our staff are notified of all applicable risk assessments and updates, along with ‘quick guides’ automatically via our e-learning system.

Develop.
Access.
Innovate.

Bionical Emas is the only CRO to combine Clinical Development, Early Access Programs and Clinical Trial Supply, to deliver a unique, seamless approach supporting our clients to bring new medicines to patients faster.

Our approach.

We provide a unique, combined approach to Clinical Development, Early Access Programs and Clinical Trial Supply. Our expert teams work seamlessly across our divisions, where they continuously use their experience and knowledge to plan, develop and execute projects to exceptionally high standards.

We build long-term, mutually beneficial partnerships. We listen carefully to what you tell us and share our insight to enhance results and deliver success. We are innovative but realistic in our recommendations, meeting your objectives while staying true to your culture.

Resource library.

Explore our resource section below. If you have any questions about the information or resources that you can’t see here, please get in touch and our dedicated team will come back to you shortly.

Resource LibraryCase Studies